Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on June 10, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

FDA Sanitation Supplies

Closed
75F40126Q134232Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The U.S. Food and Drug Administration’s Office of Acquisition and Grant Services is seeking sanitation supplies through a combined synopsis-solicitation for commercial items under solicitation number 75F40126Q134232, issued as a total small business set-aside under FAR 19.5. The requirement is for daily disinfectants, sterilants, detergents, and related solutions to maintain stringent hygiene standards in animal care facilities managed by the FDA Center for Biologics Evaluation and Research. Key products include brand-name or equal items such as Acidulate 150, Enviro-Kleen 500N, Wex-Cide 128, MB-10 and MB-160 chlorine dioxide tablets, Vimoba 150, Acidulate 45T HFDF, and QLI-9905Q ATP surface swabs, all designed for specific sanitation tasks including urine and mineral scale removal, surface disinfection, and contamination monitoring. The contract includes a base period from July 15, 2026, to July 14, 2027, with two optional 12-month periods extending through July 14, 2029. All supplies must be delivered FOB destination, with a specified six annual deliveries, and must comply with Section 508 accessibility standards for any ICT-related items, with contractors held responsible for remediation at their own expense if non-compliant. The solicitation mandates full compliance with the Buy American Act and Executive Order 14005, requiring disclosure of product origin, and incorporates special clauses such as accelerated payments to small business subcontractors, security prohibitions, and prohibitions against trafficking in persons. Proposals must be submitted electronically via email to Timothy Walbert by 2:00 p.m. CDT on June 12, 2026, and are evaluated under a Lowest Price Technically Acceptable process, where technical acceptability serves as a mandatory pass/fail gate before price is considered. Offerors must include Attachment 1, an Excel file with completed pricing tables, and are required to submit descriptive materials such as brochures or literature to demonstrate product compliance. Pricing must be firm through September 30, 2026, and submissions must avoid macros, executable files, or any non-compliant formats, or they will be deemed non-responsive. Invoices must be submitted electronically through the Treasury

General Info

Procurement of disinfectants and cleaning supplies for animal care facilities, small business set-aside.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

Contract Value

$99,512.46

NAICS

325612 - Polish and Other Sanitation Good ManufacturingView NAICS

Place of Performance

MD

Set-Aside

SBA

Awardee

QUIP LABORATORIES INCView Profile

Award Issued Date

Documents

(5)

WOAP Sanitation Supplies Pricing Tables

XLSXpricing-tables

Amended Attachment 1 - Pricing Tables for WOAP Sanitation Supplies

XLSXmodification

Amended RFQ 75F40126Q134232 for WOAP Sanitation Supplies

PDFrfq

RFQ 75F40126Q134232 for WOAP Sanitation Supplies

PDFrfq

Amendment 01 to FDA Solicitation 75F40126Q134232

PDFamendment

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

1 update
PhaseClosed
Posted

Combined Synopsis

Amendment 1

Contract was updated

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
Contacts1 person available
OfficeRockville, MD, 20852, USA
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
View Agency Profile
Office AddressRockville, MD, 20852, USA

Full Description

Show more

This requirement is for daily disinfectants, sterilants, detergents, and other solutions designed to maintain the highest standards of cleanliness and sanitation in active animal care facilities.  Please see attached PDF file titled "AMENDED FDA 75F40126Q134232" and Excel file titled "AMENDED Attachment 1 - Pricing Tables."

More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

Same awarding agency

NAICS: 541714
New
Federal
Human Hindbrain Organoid Functional Assay Services.
Solicitation # RFQ_CDR-2026-135968
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human induced pluripotent stem cell (iPSC)-derived hindbrain organoid functional assay services. The project aims to support in vitro research evaluating drug-induced effects on respiratory-relevant neural circuits over an eighteen-month period of performance. The scope of work is divided into two primary components: the provision of human hindbrain organoids and associated culture materials through twelve scheduled deliveries to the FDA White Oak Campus, and the performance of functional characterization services at the contractor's laboratory. Functional characterization will utilize three-dimensional multi-electrode array (3D MEA) technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Deliverables include the delivery of 96 organoids in the first shipment followed by 48 organoids in subsequent deliveries, as well as raw data, analyzed data, analysis files, and comprehensive study reports. This acquisition is conducted as a commercial service under FAR Part 12, with the government restricting competition based on market research identifying OrganoTherapeutics SARL as the only source capable of meeting the complete requirement for both the specific organoid products and the associated functional assay services.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 13 hours ago

DEADLINE

in 6 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS